Login / Signup

Adolescents with chronic hepatitis C might be good candidates for direct-acting antiviral therapy.

Ken SatoYuichi YamazakiYuki KanayamaDaisuke UeharaHiroki TojimaTakayoshi SugaSatoru KakizakiNaondo SoharaNorio HoriguchiMasashi Namikawa
Published in: Clinical case reports (2022)
Three Japanese adolescents with chronic hepatitis C were treated by direct-acting antivirals (DAAs). No adverse events or laboratory abnormalities were observed during and after DAA therapy, and a sustained virological response was achieved in all cases. The emotional functioning of the patients and their mothers were improved after DAA therapy.
Keyphrases
  • young adults
  • physical activity
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • peritoneal dialysis
  • stem cells
  • liver fibrosis
  • hiv infected patients
  • replacement therapy